JP2020529208A - 局所皮膚低栄養状態の治療 - Google Patents

局所皮膚低栄養状態の治療 Download PDF

Info

Publication number
JP2020529208A
JP2020529208A JP2020505253A JP2020505253A JP2020529208A JP 2020529208 A JP2020529208 A JP 2020529208A JP 2020505253 A JP2020505253 A JP 2020505253A JP 2020505253 A JP2020505253 A JP 2020505253A JP 2020529208 A JP2020529208 A JP 2020529208A
Authority
JP
Japan
Prior art keywords
mrna
fgf2
skin
fgf7
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529208A5 (https=
Inventor
マルクス・マントラー
フランク・マットナー
ヴァルター・シュミット
アヒム・シュネーベルガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accanis Biotech F&e & Co Kg GmbH
Original Assignee
Accanis Biotech F&e & Co Kg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accanis Biotech F&e & Co Kg GmbH filed Critical Accanis Biotech F&e & Co Kg GmbH
Publication of JP2020529208A publication Critical patent/JP2020529208A/ja
Publication of JP2020529208A5 publication Critical patent/JP2020529208A5/ja
Priority to JP2023115343A priority Critical patent/JP2023145532A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020505253A 2017-07-31 2018-07-31 局所皮膚低栄養状態の治療 Pending JP2020529208A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115343A JP2023145532A (ja) 2017-07-31 2023-07-13 局所皮膚低栄養状態の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183990.5A EP3437650A1 (en) 2017-07-31 2017-07-31 Treatment of local skin hypotrophy conditions
EP17183990.5 2017-07-31
PCT/EP2018/070712 WO2019025431A1 (en) 2017-07-31 2018-07-31 TREATMENT OF LOCAL SKIN HYPOTROPHIC CONDITIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115343A Division JP2023145532A (ja) 2017-07-31 2023-07-13 局所皮膚低栄養状態の治療

Publications (2)

Publication Number Publication Date
JP2020529208A true JP2020529208A (ja) 2020-10-08
JP2020529208A5 JP2020529208A5 (https=) 2021-09-09

Family

ID=59506101

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505253A Pending JP2020529208A (ja) 2017-07-31 2018-07-31 局所皮膚低栄養状態の治療
JP2023115343A Withdrawn JP2023145532A (ja) 2017-07-31 2023-07-13 局所皮膚低栄養状態の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115343A Withdrawn JP2023145532A (ja) 2017-07-31 2023-07-13 局所皮膚低栄養状態の治療

Country Status (8)

Country Link
US (1) US20200369738A1 (https=)
EP (2) EP3437650A1 (https=)
JP (2) JP2020529208A (https=)
KR (1) KR20200035073A (https=)
CN (1) CN111050785A (https=)
AU (1) AU2018311128A1 (https=)
CA (1) CA3070880A1 (https=)
WO (1) WO2019025431A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012683A (es) * 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
US20220015986A1 (en) * 2020-07-16 2022-01-20 Hillary Hayman Three-step process for mimicking plastic surgery results
CN114717230B (zh) * 2021-01-05 2024-09-03 麦塞拿治疗(香港)有限公司 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF
KR102432810B1 (ko) * 2021-10-29 2022-08-16 주식회사 엣지케어 약물전달 시스템 및 약물전달 시스템의 동작방법
WO2024151673A2 (en) * 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
CN120137909A (zh) * 2025-03-12 2025-06-13 广州酷奇圈科研与推广应用有限公司 重组外泌体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009119073A1 (ja) * 2008-03-28 2009-10-01 北海道公立大学法人札幌医科大学 皮膚の老化や瘢痕の治療剤
JP2017510542A (ja) * 2014-01-31 2017-04-13 ファクター バイオサイエンス インコーポレイテッド 核酸生成及び送達のための方法及び製品

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1168997B1 (en) 1999-04-02 2013-04-24 KCI Licensing, Inc. Vacuum assisted closure system with provision for introduction of agent
US7202226B2 (en) * 2000-10-23 2007-04-10 Detroit R & D Augmentation of wound healing by elF-4E mRNA and EGF mRNA
KR20060123256A (ko) * 2003-11-11 2006-12-01 가부시키가이샤 시세이도 모발의 태모화 방법 및 조성물
US7816140B2 (en) 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
RU2008128451A (ru) * 2005-12-14 2010-01-20 Огенодженесис, Инк. (US) Композиция для лечения и ухода за кожей, способ ее получения, способ ее использования
US20100143289A1 (en) 2006-12-19 2010-06-10 Michael Cohen Umbilical cord stem cell secreted product derived topical compositions and methods of use thereof
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
US8759287B2 (en) 2011-04-12 2014-06-24 M-3 Biologics, Llc Methods of decreasing incisional hernia formation and acute wound failure in obese patients by administering basic fibroblast growth factor
WO2013002331A1 (ja) * 2011-06-28 2013-01-03 株式会社バイオセレンタック 皮膚治療用微細針集積型製剤
US9439940B2 (en) 2011-07-19 2016-09-13 Neville Pharmaceutical, Inc. Topical transdermal method for delivering nutrients through the skin for expeditied wound healing and skin rejuvenation
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
WO2016100820A2 (en) 2014-12-19 2016-06-23 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009119073A1 (ja) * 2008-03-28 2009-10-01 北海道公立大学法人札幌医科大学 皮膚の老化や瘢痕の治療剤
JP2017510542A (ja) * 2014-01-31 2017-04-13 ファクター バイオサイエンス インコーポレイテッド 核酸生成及び送達のための方法及び製品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NUCLEIC ACIDS RESEARCH, vol. 31, no. 8, JPN6022028353, 2003, pages 2242 - 2251, ISSN: 0005011970 *
PROC. NATL. ACAD. SCI. USA, vol. 94, JPN6022028356, 1997, pages 2410 - 2414, ISSN: 0005011971 *

Also Published As

Publication number Publication date
EP3661540A1 (en) 2020-06-10
JP2023145532A (ja) 2023-10-11
CA3070880A1 (en) 2019-02-07
CN111050785A (zh) 2020-04-21
WO2019025431A1 (en) 2019-02-07
EP3437650A1 (en) 2019-02-06
US20200369738A1 (en) 2020-11-26
KR20200035073A (ko) 2020-04-01
AU2018311128A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
JP2023145532A (ja) 局所皮膚低栄養状態の治療
Chereddy et al. Combined effects of PLGA and vascular endothelial growth factor promote the healing of non-diabetic and diabetic wounds
Tkalčević et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression
DK2217062T3 (en) MULTI-TARGET READY RNAi therapeutics TO ARFRI WOUND HEALING OF SKIN
Pizzino et al. Effects of the antagomiRs 15b and 200b on the altered healing pattern of diabetic mice
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
KR20100027091A (ko) 상처 치유를 위한 개선 방법 및 조성물
CN105940110A (zh) 用于核酸产生和递送的方法和产品
US20220249346A1 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
KR20150058363A (ko) 피부 노화를 방지 및/또는 개선하기 위해 사용되는 pedf-유도 폴리펩티드의 용도
KR20190133216A (ko) 비흑색종 피부암(nmsc)의 예방 및 치료
Song et al. Development of pro‐angiogenic skin substitutes for wound healing
KR20100124820A (ko) 합성 포스포디에스테르 올리고뉴클레오타이드 및 이들의 치료적 용도
Gao et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells stimulate angiogenesis in myocardial infarction via the microRNA-423-5p/EFNA3 axis
CN107982536B (zh) 一种药物作用靶点的组合物和应用
WO2020201073A1 (en) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
EP2968462B1 (en) Methods for promoting wound healing and hair growth
US10443059B2 (en) Pharmaceutical composition and method for reducing scar formation
Kolostova et al. Wound healing gene therapy: cartilage regeneration induced by vascular endothelial growth factor plasmid
EP4374870A1 (en) Codon-optimized oligonucleotide for induction of elastin de-novo synthesis in mammals
Xiao et al. Hyaluronic Acid Hydrogel‐Mediated Delivery of MSC‐Derived Exo‐FGF21 Promotes Spinal Cord Injury Repair via STAT3/SOCS3 Signaling
Pizzino THERAPEUTIC ANGIOGENESIS IN DIABETES-RELATED IMPAIRED WOUND HEALING
CA2878758A1 (en) Method of treating wounds with penostin and/or ccn2
US20220193111A1 (en) Method of Treatment
Murillo et al. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/ijc. 29801

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314